Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023
February 07, 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2022 financial results before the open of the U.S. financial...
RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500
January 11, 2023 11:00 ET
|
Esperion Therapeutics, Inc.
CONCORD, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- RFK Racing has announced that Esperion Therapeutics, a Michigan-based pharmaceutical company, has partnered with the team for a multi-year agreement...
Esperion Appoints Ben Halladay Chief Financial Officer
November 16, 2022 16:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Ben Halladay, MBA, has been promoted to the role of Chief Financial Officer (CFO) from his prior...
Esperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus
November 09, 2022 08:00 ET
|
Esperion Therapeutics, Inc.
– Event to Include Expert-Led Discussions on State of Cardiovascular Disease Treatments and Remaining Unmet Needs – – Esperion Leadership Will Provide Overview of its Investigational Pipeline,...
Esperion to Participate in Jefferies London Healthcare Conference
November 02, 2022 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and CEO, Sheldon Koenig, will present at the Jefferies London Healthcare Conference on...
Esperion Reports Third Quarter 2022 Financial Results and Provides Company Update
November 01, 2022 07:00 ET
|
Esperion Therapeutics, Inc.
– CLEAR Outcomes Trial Achieved Last Patient Last Visit in October Ensuring Timely Trial Completion – – Remain On Track to Report Topline Results in January 2023, with Full Results Targeted to be...
Esperion Hosting Virtual Research & Development Day
October 27, 2022 08:00 ET
|
Esperion Therapeutics, Inc.
– Overview of its investigational pipeline, planned scientific focus, and future growth drivers – – Wednesday, November 9th @ 10amET – ANN ARBOR, Mich., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Esperion...
Esperion to Report Third Quarter 2022 Financial Results November 1, 2022
October 17, 2022 08:02 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2022 financial results before the open of the U.S. financial markets on...
Esperion Announces Establishment of Scientific Advisory Board to Support Pipeline and Life Cycle Management
July 25, 2022 15:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., July 25, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the establishment of its Scientific Advisory Board (SAB). The inaugural members of the Esperion SAB...
Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any Statin
June 03, 2022 12:30 ET
|
Esperion Therapeutics, Inc.
– Less than 1 in 10 were on any non-statin lipid lowering therapy – – Findings were shared at the National Lipid Association Scientific Sessions – ANN ARBOR, Mich., June 03, 2022 (GLOBE...